Category - Developments

Developments

Ocutrx Vision reports enhanced functional vision in AMD patients using Oculenz headset

Closely-held Ocutrx Vision Technologies reported that its augmented reality (AR) glasses significantly improved functional vision compared with standard near correction glasses, or no correction, in subjects with...

June 17, 2019

Developments

ContraVir posts positive human liver results from NASH drug candidate

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported positive findings from its first study with human precision cut liver slice cultures.

June 17, 2019

Developments

Enanta Pharma reports topline results from Phase 2a RSV trial

Enanta Pharmaceuticals (NASDAQ:ENTA) reported that, compared with placebo, EDP-938 significantly reduced viral load and resolved clinical symptoms in healthy adults infected with respiratory syncytial virus (RSV).

June 14, 2019

Developments

Karyopharm Therapeutics reports new selinexor combination data in multiple myeloma

Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.

June 14, 2019

Developments

Kura Oncology reports positive Phase 2 data of tipifarnib in lymphoma

Kura Oncology (NASDAQ:KURA) provided updated interim data from its Phase 2 trial of tipifarnib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

June 14, 2019

Developments

Progenics Pharma doses first prostate cancer patient in Phase 2 radiotherapy trial

Progenics Pharmaceuticals (NASDAQ:PGNX) dosed the first patient in a Phase 2 clinical study evaluating I-131 1095 radiotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC).

June 13, 2019

Developments

NuCana gets FDA’s orphan drug designation for acelarin

NuCana (NASDAQ:NCNA) received the FDA’s orphan drug designation for acelarin, a nucleoside analog of gemcitabine, for the treatment of biliary tract cancer.

June 13, 2019

Developments

InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

InflaRx (NASDAQ:IFRX) treated the first patient in a Phase 2a trial of IFX-1, an injectable antibody drug, in pyoderma gangraenosum (PG) patients.

June 13, 2019

Developments

Nuvectra seeking FDA conditional approval for full-body MR imaging for Algovita

Nuvectra (NASDAQ:NVTR) filed a regulatory submission with the FDA for conditional approval of full-body magnetic resonance (MR) imaging in patients implanted with the company’s Algovita spinal cord stimulation (SCS)...

June 12, 2019

Developments

ContraVir Pharma CRV431 data published in PLOS ONE

ContraVir Pharmaceuticals (NASDAQ:CTRV) CRV431 data from an experimental model of hepatitis B virus (HBV) has been published in the peer-reviewed journal, PLOS ONE.

June 11, 2019

Category - Developments

Subscribe